前瞻性验证两种血液基因组评估(PPQ与NETest)判定177Lu-DOTATATE治疗神经内分泌肿瘤临床疗效的中期分析
在纪念斯隆凯特琳癌症中心前瞻性收集67例接受177Lu-DOTATATE治疗的生长抑素受体阳性胃肠胰及肺神经内分泌肿瘤患者,验证PPQ对疗效的预测作用和NETest的监测作用。PPQ准确预测96%(64/67),12个月疾病控制率PPQ阳性组97% vs PPQ阴性组26%(P<0.0001)。NETest变化与治疗反应相关(准确率90%),组织基因检测与PRRT反应无关。
要点
- PPQ准确预测177Lu-DOTATATE疗效达96%(64/67),风险比24.4(95%CI 8.2-72.5)。
- 12个月疾病控制率PPQ阳性组97% vs PPQ阴性组26%(P<0.0001)。
- NETest变化与治疗反应相关(准确率90%),组织基因检测对PRRT预测价值有限。
核心结论
- 中期分析确认PPQ是177Lu-DOTATATE反应性(放射敏感性)的准确预测指标。
- NETest变化与治疗反应准确相关。
- 基于组织的分子遗传信息对PRRT预测价值有限。
研究设计与样本
- 前瞻性收集纪念斯隆凯特琳癌症中心接受177Lu-DOTATATE治疗的生长抑素受体阳性胃肠胰及肺神经内分泌肿瘤患者数据(n=67;中位年龄66岁;52%女性;42%胰腺、39%小肠;78%为1级或2级)。
- 所有病例均为转移性(89%肝转移),既往接受1-8种治疗(中位3种),包括生长抑素类似物(91%)、手术(55%)或化疗(49%)。
- 治疗反应包括无进展生存期(PFS),按RECIST 1.1版,应答者为疾病稳定或部分缓解(疾病控制率),无应答者为进展。
- 每周期前及随访时采集血液,样本去标识后行盲法检测分析;基因表达检测包括RNA分离、实时定量聚合酶链反应和多算法分析。
- 基线测定PPQ(阳性预测应答者,阴性预测无应答者),并行NETest(0-100评分);对存档肿瘤组织通过机构平台(Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets)行二代测序。
主要发现
- 41例患者(61%)为应答者,PPQ准确预测96%(64/67),预测的风险比为24.4(95%CI 8.2-72.5)。
- 12个月疾病控制率PPQ阳性患者为97% vs PPQ阴性患者为26%(P<0.0001)。
- 预测应答者(PPQ阳性,n=40)中位无进展生存期未达到,预测不应答者(PPQ阴性,n=27)为8个月。
- 应答者NETest基线为67±25,随访时显著下降(-37±44%)(P<0.05);无应答者基线为44±23,进展时显著升高(+76%±56%)(P<0.05);NETest变化(升高或降低)总体准确率90%。
- 30例患者行二代测序,肿瘤为微卫星稳定,中位突变负荷1.8,改变主要涉及mTOR/PTEN/TSC通路(30%),与PRRT反应无关联。
关键数值与推荐
- PPQ阳性预测应答者、阴性预测无应答者,准确预测96%(64/67),风险比24.4(95%CI 8.2-72.5)。
- 12个月疾病控制率PPQ阳性组97% vs PPQ阴性组26%(P<0.0001)。
- 中位无进展生存期PPQ阳性组(n=40)未达到 vs PPQ阴性组(n=27)8个月。
- NETest应答者基线67±25、随访下降-37±44%(P<0.05);无应答者基线44±23、进展时升高+76%±56%(P<0.05);NETest变化准确率90%。
- 二代测序30例:微卫星稳定,中位突变负荷1.8,mTOR/PTEN/TSC通路改变占30%,与PRRT反应无关联。
临床怎么用
- 血液基因特征可通过提供肿瘤放射敏感性和疾病进程信息,可能改善接受177Lu-DOTATATE治疗患者的管理,从而实现个体化策略。
- PPQ可用于预测177Lu-DOTATATE的放射敏感性(应答与否)。
- NETest变化可监测治疗反应并与疗效相关。
- 基于组织的分子遗传信息对PRRT预测价值有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reliable biomarkers for neuroendocrine tumor (NET) management during peptide receptor radionuclide therapy (PRRT) are lacking. We validated the role of 2 circulating biomarkers: the PRRT prediction quotient (PPQ) as a predictive marker for response and the NETest as a monitoring biomarker. Furthermore, we evaluated whether tissue-based genetic alterations are effective in predicting progression-free survival (PFS). Methods: Data were prospectively collected on patients at the Memorial Sloan Kettering Cancer Center with 177Lu-DOTATATE-treated somatostatin receptor (SSTR)-positive gastroenteropancreatic and lung NETs (n = 67; median age, 66 y; 52% female; 42% pancreatic, 39% small-bowel; 78% grade 1 or 2). All cases were metastatic (89% liver) and had received 1-8 prior treatments (median, 3), including somatostatin analogs (91%), surgery (55%), or chemotherapy (49%). Treatment response included PFS. According to RECIST, version 1.1, responders had stable disease or a partial response (disease-control rate) and nonresponders had progression. Blood was collected before each cycle and at follow-up. Samples were deidentified and assayed and underwent masked analyses. The gene expression assays included RNA isolation, real-time quantitative polymerase chain reaction, and multialgorithm analyses. The PPQ (positive predicts a responder; negative predicts a nonresponder) at baseline was determined. The NETest (0-100 score) was performed. Statistics were analyzed using Mann-Whitney U testing (2-tailed) or Kaplan-Meier survival testing (PFS). In patients with archival tumor tissue, next-generation sequencing was performed through an institutional platform (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets). Results: Forty-one patients (61%) were responders. PPQ accurately predicted 96% (64/67). The hazard ratio for prediction was 24.4 (95% CI, 8.2-72.5). Twelve-month disease control was 97% for PPQ-positive patients versus 26% for PPQ-negative patients (P < 0.0001). Median progression-free survival was not reached in those predicted to respond (PPQ-positive, n = 40) but was 8 mo in those predicted not to respond (PPQ-negative, n = 27). The NETest result in responders was 67 ± 25 at baseline and significantly (P < 0.05) decreased (-37 ± 44%) at follow-up. The NETest result in nonresponders was 44 ± 23 at baseline and significantly (P < 0.05) increased (+76% ± 56%) at progression. Overall, the NETest changes (increases or decreases) were 90% accurate. Thirty patients underwent next-generation sequencing. Tumors were microsatellite-stable, and the median mutational burden was 1.8. Alterations involved mainly the mTOR/PTEN/TSC pathway (30%). No relationship was associated with PRRT response. Conclusion: Our interim analysis confirmed that PPQ is an accurate predictor of 177Lu-DOTATATE responsiveness (radiosensitivity) and that NETest changes accurately correlated with treatment response. Tissue-based molecular genetic information had little value in PRRT prediction. Blood-based gene signatures may improve the management of patients undergoing 177Lu-DOTATATE by providing information on tumor radiosensitivity and disease course, thus allowing individualized strategies.
引用
- Bodei L, Raj N, Do RK, et al. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors. J Nucl Med. 2022. PMID: 36396457. doi:10.2967/jnumed.122.264363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。